The meeting covered four key proposals: director elections, executive compensation, auditor ratification, and an expanded long-term incentive plan. A quorum was confirmed, voting was conducted, and governance protocols were followed.Based on Workhorse Group AGM 2026 Audio Transcript — Jun. 29 2026T…
Revenue rose 12% to $327.1 million, driven by the Rex acquisition and growth in ground support equipment, while a $111.2 million non-cash bargain purchase gain from Rex led to net income of $78.0 million despite an operating loss. Integration of Rex and contract renewals with FedEx remain key prior…
Revenue grew 24% YoY to $620m, with EBITDA up 182% and net profit at $120m, driven by strong nickel and gold performance. EMAS achieved first gold sales and a resource upgrade, while MBMA and MDKA maintained strong margins and liquidity.Original document: PT Merdeka Copper Gold Tbk [MDKA] Slides Re…
The company is expanding its digital payment infrastructure through SaaS and global markets, targeting 70%-80% annual growth. Product innovation in RegTech and Super App, along with a focus on PSU and cooperative banks, is expected to drive higher margins and operational scale. International expans…
Revenue grew to $3.66m in FY25, driven by strong Tutivia adoption and new payor agreements. Loss after tax widened to $6.93m, but recent equity raises support further commercial expansion. Material uncertainty remains over funding needs before end-2026.Original document: Verici Dx Plc [VRCI] Annual…
Revenues grew modestly, but a large net loss was recorded due to a significant loss transfer from a subsidiary. Liquidity and going concern depend on the successful sale of Centor Inc. and compliance with financial covenants, with substantial uncertainties highlighted by the auditor.Original docume…
The acquisition adds long-duration, recurring cash flows and diversifies the portfolio with commercial, royalty, and development-stage assets. Non-recourse financing and tax attributes enhance capital efficiency, while market exclusivity for YUPELRI® and milestone payments reduce risk and support l…
Revenue and gross margin rose sharply year-over-year, with net and adjusted EBITDA losses narrowing due to operational improvements and cost discipline. Wholesale growth offset eCommerce declines, and $12M in new financing strengthened liquidity for future expansion.Original document: Perfect Momen…
FDA accepted the BLA resubmission for RP1 in advanced melanoma, with a decision expected by August 2026. Cash reserves declined to $268.9 million, funding operations into early 2027. RP1 and RP2 clinical programs showed strong survival and response rates in recent trials.Original document: Replimun…
Net loss increased to $313.9M in FY 2026, with cash runway into Q1 2027 and no product revenue. RP1 BLA for advanced melanoma remains under FDA review after two CRLs; a 55% workforce reduction was implemented. Continued operations depend on regulatory approval or new financing.Original document: Re…
Cash position strengthened to $157.3M, but net loss widened to $148.0M year-over-year, driven by increased R&D and administrative expenses. Major equity and debt financings completed, with no impairment recognized on goodwill or intangibles.Original document: Cybin, Inc. [HELP] SEC 8-K Current Repo…
NGN-401 gene therapy in Phase 1/2 for Rett syndrome showed durable, multidomain developmental gains in all participants, with rapid onset and deepening effects over time. The therapy was well-tolerated, with no new safety concerns, and led to increased independence and reduced caregiver burden. Emb…
Two proprietary programs, HLP003 for MDD and HLP004 for GAD, have shown rapid, durable efficacy and favorable safety in Phase 2 trials, with HLP003 in Phase 3 and strong patent protection through 2041. The company is well-funded and positioned to address large unmet needs in mental health.Original…
Revenue and EBITDA saw strong double-digit growth, driven by ecosystem expansion beyond food delivery and robust performance in fintech, ads, and travel. AI integration is accelerating operational efficiency, while increased investment in iFood and JET is expected to temporarily flatten profitabili…
Revenue grew 9.8% to $23.6M with gross margin expanding to 67.6%, while net loss narrowed to $7.1M. Wholesale drove growth, but ongoing losses and a delisting from NYSE American raise going concern risks. The company is focused on margin improvement, digital expansion, and securing additional finan…
NGN-401 gene therapy showed durable, progressive gains in developmental milestones for Rett syndrome patients, with all participants improving and no loss of milestones through 30 months. The therapy remains well-tolerated, and no serious adverse events were reported.Original document: Neurogene In…
The company is expanding its digital payment infrastructure through SaaS and global markets, targeting 70%-80% annual growth and higher margins by FY 2029. Product innovation, AI adoption, and a disciplined acquisition strategy underpin its outlook, with a strong pipeline in TSP, PPaaS, and RegTech…
Lumvoa received FDA approval as the first treatment for both active and chronic TED, showing rapid and durable efficacy in pivotal trials. Launch strategies target rapid uptake in a large, underpenetrated market, with robust patient support and payer engagement.Original document: Viridian Therapeut…
Individualized neoantigen vaccine programs TG4050 and TG4070 are advancing in early-stage HNSCC and NSCLC, with TG4050 showing 100% 2-year DFS in Phase 1 and Phase 2 efficacy data expected by Q1 2028. Scalable cell line manufacturing and AI-driven neoantigen selection support expansion, while the c…
Revenue and EBITDA surged, driven by ecosystem expansion beyond food delivery into fintech, travel, and ads, with AI-powered efficiency and cross-segment synergies. Investments will temporarily weigh on margins, but long-term profitability and growth remain on track.Based on Prosus N.V. Class N [PR…
